(4R,9aS)-4-(3,4,5-trifluorophenyl)-3,4,7,9a-tetrahydro-1H-pyrido[2,1-c][1,4]oxazin-6-one | 937816-16-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4R,9aS)-4-(3,4,5-trifluorophenyl)-3,4,7,9a-tetrahydro-1H-pyrido[2,1-c][1,4]oxazin-6-one
• CAS: 937816-16-5
• 化学式: C₁₄H₁₂F₃NO₂
• 分子量: 283.25
• InChiKey: RIMFCYWFMAPGLG-CABZTGNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4R,9aS)-4-(3,4,5-trifluorophenyl)-3,4,7,9a-tetrahydro-1H-pyrido[2,1-c][1,4]oxazin-6-one 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 (4R,9aS)-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one
  参考文献：
  名称：

  Prodrug of cinnamide compound

  摘要：

  本发明提供了一种桂皮酰胺化合物的最适宜的前药。该前药由式（I）表示，其中R a 和R b 分别表示C1-6烷基或类似物；X a 表示甲氧基或氟原子；Y表示磷酸酯基团或类似物；A表示环内酰胺衍生物。

  公开号：

  US20090048213A1
• 作为产物：
  描述：

  (E)-3-[(3S,5R)-4-(3-butenoyl)-5-(3,4,5-trifluorophenyl)morpholin-3-yl]acrylic acid methyl ester 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.67h， 生成 (4R,9aS)-4-(3,4,5-trifluorophenyl)-3,4,7,9a-tetrahydro-1H-pyrido[2,1-c][1,4]oxazin-6-one
  参考文献：
  名称：

  Prodrug of cinnamide compound

  摘要：

  本发明提供了一种桂皮酰胺化合物的最适宜的前药。该前药由式（I）表示，其中R a 和R b 分别表示C1-6烷基或类似物；X a 表示甲氧基或氟原子；Y表示磷酸酯基团或类似物；A表示环内酰胺衍生物。

  公开号：

  US20090048213A1

文献信息

• Two cyclic cinnamide compound
  申请人：Kimura Teiji

  公开号：US20070117839A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

  本发明涉及一种新型的二环丙烯酰胺化合物和包含该化合物作为活性成分的药物。所述二环丙烯酰胺化合物由通式（I）表示：其中，表示单键或双键；Ar1表示苯基或吡啶基，可以被1至3个取代基取代；R1和R2分别表示C1-6烷基、羟基或类似物；Z1表示亚甲基或乙烯基，可以被从取代基A1中选择的1或2个取代基、氧原子或取代基A1选择的亚胺基取代；p、q和r分别表示0至2的整数，具有降低Aβ40和Aβ42生成的作用，因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病，如阿尔茨海默病或唐氏综合症的药物。
• TWO CYCLIC CINNAMIDE COMPOUND
  申请人：Kimura Teiji

  公开号：US20090181945A1

  公开（公告）日：2009-07-16

  The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

  本发明涉及一种新型的双环肉桂酰胺化合物和一种以该化合物为活性成分的药物制剂。该双环肉桂酰胺化合物由通式（I）表示：其中，表示单键或双键；Ar1表示苯基或吡啶基，可以用1至3个取代基取代；R1和R2各表示C1-6烷基、羟基或类似物；Z1表示亚甲基或乙烯基，可以用来自取代基A1的1或2个取代基、氧原子或可用取代基A1取代的亚胺基取代；p、q和r各表示0至2的整数，具有减少Aβ40和Aβ42产生的作用，因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病，如阿尔茨海默病或唐氏综合症的药物制剂。
• BICYCLIC CINNAMIDE COMPOUND
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1953158A1

  公开（公告）日：2008-08-06

  A bicyclic cinnamide compound represented by the general formula (I): wherein ---- represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group optionally substituted by one to three substituents; R1 and R2 each represents a C1-6 alkyl group, a hydroxyl group, etc.; Z1 represents an optionally substituted methylene group or vinylene group, an oxygen atom, or an imino group optionally substituted by a Cl-6 alkyl group or a Cl-6 acyl group; and p, q, and r each is an integer of 0 to 2. It functions to reduce Aβ40 and Aβ42. It is hence useful especially as a prevention or remedy for neurodegenerative diseases of which Aβ is causative, such as Alzheimer's disease and Down's syndrome.

  由通式(I)代表的双环肉桂化合物： 其中 ---- 代表单键或双键；Ar1 代表任选被一至三个取代基取代的苯基或吡啶基；R1 和 R2 分别代表 C1-6 烷基、羟基等；Z1 代表任选被取代的亚甲基或亚乙烯基、氧原子或任选被 Cl-6 烷基或 Cl-6 丙烯酸基取代的亚氨基；p、q 和 r 分别为 0 至 2 的整数。 它具有降低 Aβ40 和 Aβ42 的功能。因此，它特别适用于预防或治疗 Aβ 导致的神经退行性疾病，如阿尔茨海默氏症和唐氏综合症。
• PRODRUG OF CINNAMIDE COMPOUND
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2048143A1

  公开（公告）日：2009-04-15

  Disclosed is an optimal prodrug of a cinnamide compound represented by Formula (I) below. In the formula, Ra and Rb respectively represent a C1-6 alkyl group or the like; Xa represents a methoxy group or a fluorine atom; Y represents a phosphono group or the like; and A represents a cyclic lactam derivative.

  本发明公开了下式（I）所代表的肉桂酰胺化合物的最佳原药。 式中，Ra 和 Rb 分别代表 C1-6 烷基或类似基团；Xa 代表甲氧基或氟原子；Y 代表膦酰基或类似基团；A 代表环内酰胺衍生物。
• US7737141B2
  申请人：——

  公开号：US7737141B2

  公开（公告）日：2010-06-15